Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sirolimus in the Treatment of Histological Defined Chronic Allograft Nephropathy

NCT00282217 is registered in ClinicalTrials.gov with Wyeth is now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT00282217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00282217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sirolimus in the Treatment of Histological Defined Chronic Allograft Nephropathy
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2006
Completion date
Not reported
Enrollment
100
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

kidney diseases, kidney failure